What is the significance and treatment of p16 positive Carcinoma of Unknown Primary (CUP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

p16 Positive Carcinoma of Unknown Primary (CUP)

p16-positive CUP represents a favorable-prognosis subset of cancer of unknown primary, most commonly indicating an HPV-associated squamous cell carcinoma with an occult oropharyngeal primary, and should be treated with neck dissection and/or radiotherapy-chemotherapy analogous to head and neck squamous cell carcinoma rather than empiric CUP regimens. 1

Definition and Clinical Significance

p16-positive CUP is defined as squamous cell carcinoma presenting in non-supraclavicular cervical lymph nodes without a detectable mucosal primary tumor, where immunohistochemistry demonstrates p16 overexpression. 1 This represents approximately 63% of head and neck CUP cases and constitutes one of the favorable-prognosis CUP subtypes (comprising 15-20% of all CUP patients). 1, 2

Biological and Prognostic Implications

  • Primary tumor localization: p16 positivity strongly predicts an occult oropharyngeal primary, particularly in the tonsils or base of tongue, as HPV-associated malignancies preferentially arise in these locations. 3, 4

  • Superior survival outcomes: Patients with p16-positive CUP demonstrate significantly improved 5-year overall survival (69% vs 33% for p16-negative; p=0.045) and 3-year disease-free survival (79% vs 56%; p=0.012) compared to p16-negative disease. 3, 2

  • Less aggressive nodal disease: p16-positive tumors present with less advanced nodal status (N1-N2b in 52% vs 89% for p16-negative; p=0.035), allowing for potentially less intensive treatment approaches. 2

Diagnostic Workup Algorithm

Mandatory Initial Assessment

When squamous cell carcinoma is identified in cervical lymph nodes:

  • Perform flexible endoscopy, contrast-enhanced CT and/or preferably MRI of the head and neck, plus FDG-PET imaging to locate the primary. 1

  • If primary remains undetected, proceed to panendoscopy with directed biopsies of the nasopharynx, hypopharynx, and oropharynx, plus bilateral tonsillectomy. 1

  • Test carcinoma tissue for p16 expression by immunohistochemistry, and if positive, confirm HPV status. 1

  • Determine Epstein-Barr virus (EBV) status and consider PD-L1 expression analysis for relapsed or metastatic disease. 1

Prognostic Refinement

While p16 positivity alone indicates favorable prognosis, combining p16 status with Ki-67 proliferation index may provide more accurate prediction of locoregional control—all p16-positive patients with low Ki-67 demonstrated excellent locoregional control in clinical series. 5 However, this combination is not yet incorporated into standard guidelines.

Treatment Recommendations

Localized Disease (Non-Distant Metastatic)

Treatment should mirror head and neck squamous cell carcinoma protocols, NOT standard empiric CUP chemotherapy regimens. 1

For small-volume neck disease (N1-N2b):

  • Choose either neck dissection OR radiotherapy-chemotherapy (RT-ChT) as single modality treatment. 1

For large-volume neck disease (≥N2c):

  • Combine both neck dissection AND radiotherapy-chemotherapy. 1

Metastatic/Relapsed Disease

For patients with distant metastases or relapsed disease, emerging evidence supports immunotherapy-based approaches:

  • Pembrolizumab plus 5-fluorouracil and cisplatin demonstrated remarkable efficacy in a case report of p16-positive squamous cell CUP with widespread metastases, achieving marked tumor reduction after just two cycles. 6

  • This combination should be strongly considered for p16-positive CUP with unfavorable features (distant metastases, poor performance status), particularly given the established role of PD-L1 inhibitors in HPV-associated head and neck cancers. 6

Critical Clinical Pitfalls

Common Errors to Avoid

  1. Treating p16-positive CUP with empiric platinum-doublet regimens (carboplatin-paclitaxel, cisplatin-gemcitabine) used for unfavorable CUP—this ignores the favorable biology and site-specific treatment opportunities. 1

  2. Failing to perform bilateral tonsillectomy during panendoscopy—this is essential as occult tonsillar primaries are frequently identified only on pathologic examination. 1

  3. Assuming all p16-positive patients have identical outcomes—age remains an independent prognostic factor, and nodal burden still influences treatment intensity decisions. 5, 2

  4. Omitting p16 testing in cervical squamous cell carcinoma—this biomarker fundamentally changes treatment approach and prognostic counseling. 1

Nuanced Considerations

The 2023 ESMO guidelines represent the most current evidence-based approach, superseding older recommendations from 2007-2015 that did not fully incorporate p16/HPV biology into treatment algorithms. 1 While earlier guidelines mentioned p16 testing, they did not explicitly stratify treatment intensity based on p16 status as strongly as current practice supports. 1

There is no definitive consensus on whether surgery or radiotherapy should be preferred for local treatment when both are options, though breast radiotherapy data in other CUP subtypes suggests RT may spare patients from surgery with equivalent outcomes—this principle may apply to neck disease as well. 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

5
Research

Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2019

Related Questions

How do you diagnose C. diff infection in a patient with diarrhea undergoing chemoradiation with cisplatin for p16+ squamous cell carcinoma of the tongue?
What is the appropriate management for a 65-year-old male with macrocytic anemia, positive dengue and typhoid IgM, and a peripheral blood smear showing macrocytes, target cells, and tear-drop cells?
What is the best approach to treat a 53-year-old patient with newly diagnosed type 2 diabetes (T2D) and a Hemoglobin A1c (HbA1c) level of 12%?
What is the optimal management plan for a patient with a history of stroke, hypertension (HTN), hyperlipidemia (HLD), chronic obstructive pulmonary disease (COPD), gout, and an enlarged ascending thoracic aorta?
What is the management approach for an adrenal nodule?
Can macrocytic anemia with macrocytes, target cells, and tear-drop cells on peripheral blood smear be thalassemia?
What is the treatment approach for Gastrointestinal Stromal Tumors (GIST) with specific mutations?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question